EUVIMEDEUVIMED entdecken
CrossrefInfokarte

Foslevodopa/Foscarbidopa Overnight Administration Improves Nocturia in Patients with Parkinson's Disease: Evidence from a Real‐World Study

Livia Brusa, Carla Piano, Elias Paolo Casula, Massimo Marano, Antonio Suppa, Alessandro Zampogna, Martina Patera, Stefano Toro, Jacopo Campone, Fabio Viselli, Laura Vacca, Marika Alborghetti, Alessandro Stefani, Francesco Bove

Movement Disorders Clinical Practice · 2026-09 · 13 (9) · 2199-2203

DOI: 10.1002/mdc3.70569 ↗
AbstractBibliografische Angaben

Abstract

Abstract Background Nocturia is considered as one of the commonest nonmotor symptoms in people with Parkinson's disease ( PD ), highly impacting on quality‐of‐life and health‐related costs. Objectives Aim of our real‐world study was to evaluate the impact of Foslevodopa/Foscarbidopa ( LDp / CDp ) subcutaneous infusion ( CSCI ) on nocturia in a group of advanced PD patients. Methods Seventy‐eight patients were enrolled in seven Movement Disorders outpatient clinics. International Prostatic Symptoms Scale ( IPSS ) and Nocturia Quality of Life ( NQoL ) questionnaire were administrated before starting LDp / CDp CSCI and after three months of infusion. Results In this cohort, LDp / CDp CSCI significantly improved urinary disturbances, nocturia and quality of life. Age and baseline MDS ‐ UPDRS score negatively influenced urinary disturbances and quality of life changes during the treatment, while post‐pre changes of IPSS and LEED showed a negative correlation. Conclusions This study supports the utility of the overnight dopaminergic stimulation with LDp / CDp CSCI in controlling overactive bladder.

Wissen, das zu Ihrer Arbeit passt.

Vom kostenlosen Einstieg über die persönliche Recherche bis zur vollständigen Research Suite.

Tarife ansehen →

Sind alle Verlagsvolltexte enthalten?

Nein. Bibliografische Nachweise, Abstracts und Volltexte sind unterschiedliche Inhalte. Ob ein Volltext verfügbar ist, hängt von der Quelle, Open Access und Ihren vorhandenen Lizenzen ab. Ein EUVIMED-Tarif ersetzt keine zusätzlichen Verlagsrechte.

Tarife ansehen →